Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Stock Competitors & Peer Comparison
See (RCDTF) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RCDTF | $55.88 | +0.00% | 11.4B | 21.09 | $2.65 | +2.65% |
| BMYMP | $400.00 | -57.46% | 814.6B | 1777.78 | $0.23 | +4.42% |
| RHHBF | $423.20 | +0.16% | 336.9B | 20.52 | $20.62 | +2.93% |
| RHHBY | $51.09 | -0.39% | 328.7B | 19.78 | $2.58 | +3.03% |
| RHHVF | $403.29 | +8.69% | 321B | 19.64 | $20.53 | +3.08% |
| AZNCF | $189.90 | -1.35% | 294.4B | 31.49 | $6.03 | +1.41% |
| NVSEF | $142.65 | -2.12% | 272.2B | 20.44 | $6.98 | +3.32% |
| SNYNF | $86.40 | +3.49% | 103.7B | 18.58 | $4.65 | +5.60% |
| GLAXF | $25.70 | +0.00% | 102.6B | 13.32 | $1.93 | +3.50% |
| CHGCY | $25.04 | -1.84% | 82.3B | 29.76 | $0.84 | +3.28% |
Stock Comparison
RCDTF vs BMYMP Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, BMYMP has a market cap of 814.6B. Regarding current trading prices, RCDTF is priced at $55.88, while BMYMP trades at $400.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas BMYMP's P/E ratio is 1777.78. In terms of profitability, RCDTF's ROE is +0.24%, compared to BMYMP's ROE of +0.39%. Regarding short-term risk, RCDTF is less volatile compared to BMYMP. This indicates potentially lower risk in terms of short-term price fluctuations for RCDTF.Check BMYMP's competition here
RCDTF vs RHHBF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, RHHBF has a market cap of 336.9B. Regarding current trading prices, RCDTF is priced at $55.88, while RHHBF trades at $423.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas RHHBF's P/E ratio is 20.52. In terms of profitability, RCDTF's ROE is +0.24%, compared to RHHBF's ROE of +0.29%. Regarding short-term risk, RCDTF is more volatile compared to RHHBF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check RHHBF's competition here
RCDTF vs RHHBY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, RHHBY has a market cap of 328.7B. Regarding current trading prices, RCDTF is priced at $55.88, while RHHBY trades at $51.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas RHHBY's P/E ratio is 19.78. In terms of profitability, RCDTF's ROE is +0.24%, compared to RHHBY's ROE of +0.29%. Regarding short-term risk, RCDTF is more volatile compared to RHHBY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check RHHBY's competition here
RCDTF vs RHHVF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, RHHVF has a market cap of 321B. Regarding current trading prices, RCDTF is priced at $55.88, while RHHVF trades at $403.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas RHHVF's P/E ratio is 19.64. In terms of profitability, RCDTF's ROE is +0.24%, compared to RHHVF's ROE of +0.41%. Regarding short-term risk, RCDTF is less volatile compared to RHHVF. This indicates potentially lower risk in terms of short-term price fluctuations for RCDTF.Check RHHVF's competition here
RCDTF vs AZNCF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, AZNCF has a market cap of 294.4B. Regarding current trading prices, RCDTF is priced at $55.88, while AZNCF trades at $189.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas AZNCF's P/E ratio is 31.49. In terms of profitability, RCDTF's ROE is +0.24%, compared to AZNCF's ROE of +0.23%. Regarding short-term risk, RCDTF is more volatile compared to AZNCF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check AZNCF's competition here
RCDTF vs NVSEF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, NVSEF has a market cap of 272.2B. Regarding current trading prices, RCDTF is priced at $55.88, while NVSEF trades at $142.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas NVSEF's P/E ratio is 20.44. In terms of profitability, RCDTF's ROE is +0.24%, compared to NVSEF's ROE of +0.32%. Regarding short-term risk, RCDTF is more volatile compared to NVSEF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check NVSEF's competition here
RCDTF vs SNYNF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, SNYNF has a market cap of 103.7B. Regarding current trading prices, RCDTF is priced at $55.88, while SNYNF trades at $86.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas SNYNF's P/E ratio is 18.58. In terms of profitability, RCDTF's ROE is +0.24%, compared to SNYNF's ROE of +0.14%. Regarding short-term risk, RCDTF is more volatile compared to SNYNF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check SNYNF's competition here
RCDTF vs GLAXF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, GLAXF has a market cap of 102.6B. Regarding current trading prices, RCDTF is priced at $55.88, while GLAXF trades at $25.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas GLAXF's P/E ratio is 13.32. In terms of profitability, RCDTF's ROE is +0.24%, compared to GLAXF's ROE of +0.36%. Regarding short-term risk, RCDTF is more volatile compared to GLAXF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check GLAXF's competition here
RCDTF vs CHGCY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, CHGCY has a market cap of 82.3B. Regarding current trading prices, RCDTF is priced at $55.88, while CHGCY trades at $25.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas CHGCY's P/E ratio is 29.76. In terms of profitability, RCDTF's ROE is +0.24%, compared to CHGCY's ROE of +0.24%. Regarding short-term risk, RCDTF is more volatile compared to CHGCY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check CHGCY's competition here
RCDTF vs CHGCF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, CHGCF has a market cap of 80.6B. Regarding current trading prices, RCDTF is priced at $55.88, while CHGCF trades at $49.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas CHGCF's P/E ratio is 29.17. In terms of profitability, RCDTF's ROE is +0.24%, compared to CHGCF's ROE of +0.23%. Regarding short-term risk, RCDTF is more volatile compared to CHGCF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check CHGCF's competition here
RCDTF vs BAYRY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, BAYRY has a market cap of 42.8B. Regarding current trading prices, RCDTF is priced at $55.88, while BAYRY trades at $10.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas BAYRY's P/E ratio is -17.03. In terms of profitability, RCDTF's ROE is +0.24%, compared to BAYRY's ROE of -0.07%. Regarding short-term risk, RCDTF is more volatile compared to BAYRY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check BAYRY's competition here
RCDTF vs OTSKY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, OTSKY has a market cap of 37.4B. Regarding current trading prices, RCDTF is priced at $55.88, while OTSKY trades at $35.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas OTSKY's P/E ratio is 16.35. In terms of profitability, RCDTF's ROE is +0.24%, compared to OTSKY's ROE of +0.13%. Regarding short-term risk, RCDTF is more volatile compared to OTSKY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check OTSKY's competition here
RCDTF vs OTSKF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, OTSKF has a market cap of 34B. Regarding current trading prices, RCDTF is priced at $55.88, while OTSKF trades at $64.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas OTSKF's P/E ratio is 14.84. In terms of profitability, RCDTF's ROE is +0.24%, compared to OTSKF's ROE of +0.13%. Regarding short-term risk, RCDTF is more volatile compared to OTSKF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check OTSKF's competition here
RCDTF vs DSKYF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, DSKYF has a market cap of 31B. Regarding current trading prices, RCDTF is priced at $55.88, while DSKYF trades at $17.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas DSKYF's P/E ratio is 19.13. In terms of profitability, RCDTF's ROE is +0.24%, compared to DSKYF's ROE of +0.16%. Regarding short-term risk, RCDTF is more volatile compared to DSKYF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check DSKYF's competition here
RCDTF vs DSNKY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, DSNKY has a market cap of 29.6B. Regarding current trading prices, RCDTF is priced at $55.88, while DSNKY trades at $16.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas DSNKY's P/E ratio is 18.26. In terms of profitability, RCDTF's ROE is +0.24%, compared to DSNKY's ROE of +0.16%. Regarding short-term risk, RCDTF is more volatile compared to DSNKY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check DSNKY's competition here
RCDTF vs ALPMF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, ALPMF has a market cap of 28.1B. Regarding current trading prices, RCDTF is priced at $55.88, while ALPMF trades at $15.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas ALPMF's P/E ratio is 15.24. In terms of profitability, RCDTF's ROE is +0.24%, compared to ALPMF's ROE of +0.17%. Regarding short-term risk, RCDTF is less volatile compared to ALPMF. This indicates potentially lower risk in terms of short-term price fluctuations for RCDTF.Check ALPMF's competition here
RCDTF vs ALPMY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, ALPMY has a market cap of 26.3B. Regarding current trading prices, RCDTF is priced at $55.88, while ALPMY trades at $14.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas ALPMY's P/E ratio is 14.24. In terms of profitability, RCDTF's ROE is +0.24%, compared to ALPMY's ROE of +0.18%. Regarding short-term risk, RCDTF is more volatile compared to ALPMY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check ALPMY's competition here
RCDTF vs ORINY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, ORINY has a market cap of 21.4B. Regarding current trading prices, RCDTF is priced at $55.88, while ORINY trades at $37.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas ORINY's P/E ratio is 17.19. In terms of profitability, RCDTF's ROE is +0.24%, compared to ORINY's ROE of +0.49%. Regarding short-term risk, RCDTF is more volatile compared to ORINY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check ORINY's competition here
RCDTF vs GIKLY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, GIKLY has a market cap of 13.9B. Regarding current trading prices, RCDTF is priced at $55.88, while GIKLY trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas GIKLY's P/E ratio is 15.14. In terms of profitability, RCDTF's ROE is +0.24%, compared to GIKLY's ROE of +0.08%. Regarding short-term risk, RCDTF is less volatile compared to GIKLY. This indicates potentially lower risk in terms of short-term price fluctuations for RCDTF.Check GIKLY's competition here
RCDTF vs CHJTF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, CHJTF has a market cap of 12B. Regarding current trading prices, RCDTF is priced at $55.88, while CHJTF trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas CHJTF's P/E ratio is 21.00. In terms of profitability, RCDTF's ROE is +0.24%, compared to CHJTF's ROE of +0.05%. Regarding short-term risk, RCDTF is more volatile compared to CHJTF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check CHJTF's competition here
RCDTF vs ORINF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, ORINF has a market cap of 11.7B. Regarding current trading prices, RCDTF is priced at $55.88, while ORINF trades at $82.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas ORINF's P/E ratio is 18.76. In terms of profitability, RCDTF's ROE is +0.24%, compared to ORINF's ROE of +0.49%. Regarding short-term risk, RCDTF is more volatile compared to ORINF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check ORINF's competition here
RCDTF vs CSPCY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, CSPCY has a market cap of 11.5B. Regarding current trading prices, RCDTF is priced at $55.88, while CSPCY trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas CSPCY's P/E ratio is 19.90. In terms of profitability, RCDTF's ROE is +0.24%, compared to CSPCY's ROE of +0.05%. Regarding short-term risk, RCDTF is more volatile compared to CSPCY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check CSPCY's competition here
RCDTF vs GIFOF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, GIFOF has a market cap of 8.7B. Regarding current trading prices, RCDTF is priced at $55.88, while GIFOF trades at $8.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas GIFOF's P/E ratio is 12.83. In terms of profitability, RCDTF's ROE is +0.24%, compared to GIFOF's ROE of +0.08%. Regarding short-term risk, RCDTF is more volatile compared to GIFOF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check GIFOF's competition here
RCDTF vs KYKOF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, KYKOF has a market cap of 7.6B. Regarding current trading prices, RCDTF is priced at $55.88, while KYKOF trades at $14.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas KYKOF's P/E ratio is 17.59. In terms of profitability, RCDTF's ROE is +0.24%, compared to KYKOF's ROE of +0.08%. Regarding short-term risk, RCDTF is less volatile compared to KYKOF. This indicates potentially lower risk in terms of short-term price fluctuations for RCDTF.Check KYKOF's competition here
RCDTF vs OPHLY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, OPHLY has a market cap of 7.4B. Regarding current trading prices, RCDTF is priced at $55.88, while OPHLY trades at $5.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas OPHLY's P/E ratio is 17.02. In terms of profitability, RCDTF's ROE is +0.24%, compared to OPHLY's ROE of +0.09%. Regarding short-term risk, RCDTF is more volatile compared to OPHLY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check OPHLY's competition here
RCDTF vs GIFLF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, GIFLF has a market cap of 7.2B. Regarding current trading prices, RCDTF is priced at $55.88, while GIFLF trades at $10.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas GIFLF's P/E ratio is 15.32. In terms of profitability, RCDTF's ROE is +0.24%, compared to GIFLF's ROE of +0.08%. Regarding short-term risk, RCDTF is less volatile compared to GIFLF. This indicates potentially lower risk in terms of short-term price fluctuations for RCDTF.Check GIFLF's competition here
RCDTF vs OPHLF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, OPHLF has a market cap of 6.8B. Regarding current trading prices, RCDTF is priced at $55.88, while OPHLF trades at $14.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas OPHLF's P/E ratio is 15.48. In terms of profitability, RCDTF's ROE is +0.24%, compared to OPHLF's ROE of +0.09%. Regarding short-term risk, RCDTF is more volatile compared to OPHLF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check OPHLF's competition here
RCDTF vs DPHAY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, DPHAY has a market cap of 5.6B. Regarding current trading prices, RCDTF is priced at $55.88, while DPHAY trades at $98.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas DPHAY's P/E ratio is -155.56. In terms of profitability, RCDTF's ROE is +0.24%, compared to DPHAY's ROE of -0.04%. Regarding short-term risk, RCDTF is more volatile compared to DPHAY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check DPHAY's competition here
RCDTF vs SNPHY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, SNPHY has a market cap of 3.8B. Regarding current trading prices, RCDTF is priced at $55.88, while SNPHY trades at $11.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas SNPHY's P/E ratio is 16.30. In terms of profitability, RCDTF's ROE is +0.24%, compared to SNPHY's ROE of +0.11%. Regarding short-term risk, RCDTF is more volatile compared to SNPHY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check SNPHY's competition here
RCDTF vs SNPHF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, SNPHF has a market cap of 3.5B. Regarding current trading prices, RCDTF is priced at $55.88, while SNPHF trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas SNPHF's P/E ratio is 15.26. In terms of profitability, RCDTF's ROE is +0.24%, compared to SNPHF's ROE of +0.17%. Regarding short-term risk, RCDTF is more volatile compared to SNPHF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check SNPHF's competition here
RCDTF vs VRBCF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, VRBCF has a market cap of 3.4B. Regarding current trading prices, RCDTF is priced at $55.88, while VRBCF trades at $408.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas VRBCF's P/E ratio is 19.23. In terms of profitability, RCDTF's ROE is +0.24%, compared to VRBCF's ROE of +0.14%. Regarding short-term risk, RCDTF is more volatile compared to VRBCF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check VRBCF's competition here
RCDTF vs HAWPY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, HAWPY has a market cap of 3B. Regarding current trading prices, RCDTF is priced at $55.88, while HAWPY trades at $53.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas HAWPY's P/E ratio is 14.19. In terms of profitability, RCDTF's ROE is +0.24%, compared to HAWPY's ROE of +0.06%. Regarding short-term risk, RCDTF is more volatile compared to HAWPY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check HAWPY's competition here
RCDTF vs HAWPF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, HAWPF has a market cap of 2.7B. Regarding current trading prices, RCDTF is priced at $55.88, while HAWPF trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas HAWPF's P/E ratio is 12.77. In terms of profitability, RCDTF's ROE is +0.24%, compared to HAWPF's ROE of +0.06%. Regarding short-term risk, RCDTF is less volatile compared to HAWPF. This indicates potentially lower risk in terms of short-term price fluctuations for RCDTF.Check HAWPF's competition here
RCDTF vs PTKFF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, PTKFF has a market cap of 2.2B. Regarding current trading prices, RCDTF is priced at $55.88, while PTKFF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas PTKFF's P/E ratio is N/A. In terms of profitability, RCDTF's ROE is +0.24%, compared to PTKFF's ROE of +0.16%. Regarding short-term risk, RCDTF is more volatile compared to PTKFF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check PTKFF's competition here
RCDTF vs LYPHF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, LYPHF has a market cap of 1.2B. Regarding current trading prices, RCDTF is priced at $55.88, while LYPHF trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas LYPHF's P/E ratio is 14.75. In terms of profitability, RCDTF's ROE is +0.24%, compared to LYPHF's ROE of +0.04%. Regarding short-term risk, RCDTF is less volatile compared to LYPHF. This indicates potentially lower risk in terms of short-term price fluctuations for RCDTF.Check LYPHF's competition here
RCDTF vs TGRNF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, TGRNF has a market cap of 633.9M. Regarding current trading prices, RCDTF is priced at $55.88, while TGRNF trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas TGRNF's P/E ratio is 9.90. In terms of profitability, RCDTF's ROE is +0.24%, compared to TGRNF's ROE of +0.05%. Regarding short-term risk, RCDTF is more volatile compared to TGRNF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check TGRNF's competition here
RCDTF vs JCRRF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, JCRRF has a market cap of 508.7M. Regarding current trading prices, RCDTF is priced at $55.88, while JCRRF trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas JCRRF's P/E ratio is -34.75. In terms of profitability, RCDTF's ROE is +0.24%, compared to JCRRF's ROE of +0.06%. Regarding short-term risk, RCDTF is more volatile compared to JCRRF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check JCRRF's competition here
RCDTF vs MAYNF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, MAYNF has a market cap of 138.8M. Regarding current trading prices, RCDTF is priced at $55.88, while MAYNF trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas MAYNF's P/E ratio is -2.28. In terms of profitability, RCDTF's ROE is +0.24%, compared to MAYNF's ROE of -0.23%. Regarding short-term risk, RCDTF is more volatile compared to MAYNF. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check MAYNF's competition here
RCDTF vs PTKFY Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, PTKFY has a market cap of 11M. Regarding current trading prices, RCDTF is priced at $55.88, while PTKFY trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas PTKFY's P/E ratio is 10.69. In terms of profitability, RCDTF's ROE is +0.24%, compared to PTKFY's ROE of +0.16%. Regarding short-term risk, RCDTF is more volatile compared to PTKFY. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check PTKFY's competition here
RCDTF vs PSYGF Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, PSYGF has a market cap of 2M. Regarding current trading prices, RCDTF is priced at $55.88, while PSYGF trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas PSYGF's P/E ratio is -0.17. In terms of profitability, RCDTF's ROE is +0.24%, compared to PSYGF's ROE of -14.36%. Regarding short-term risk, RCDTF is less volatile compared to PSYGF. This indicates potentially lower risk in terms of short-term price fluctuations for RCDTF.Check PSYGF's competition here
RCDTF vs CRXTQ Comparison May 2026
RCDTF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCDTF stands at 11.4B. In comparison, CRXTQ has a market cap of 72.8K. Regarding current trading prices, RCDTF is priced at $55.88, while CRXTQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCDTF currently has a P/E ratio of 21.09, whereas CRXTQ's P/E ratio is -0.00. In terms of profitability, RCDTF's ROE is +0.24%, compared to CRXTQ's ROE of +0.33%. Regarding short-term risk, RCDTF is more volatile compared to CRXTQ. This indicates potentially higher risk in terms of short-term price fluctuations for RCDTF.Check CRXTQ's competition here